Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2017 347 961 M
EBIT 2017 -
Net income 2017 21 860 M
Finance 2017 48 555 M
Yield 2017 1,29%
Sales 2018 357 881 M
EBIT 2018 -
Net income 2018 24 402 M
Finance 2018 63 576 M
Yield 2018 1,36%
P/E ratio 2017 48,89
P/E ratio 2018 43,30
EV / Sales2017 3,06x
EV / Sales2018 2,93x
Capitalization 1 113 190 M
More Financials
Company
Kyowa Hakko Kirin Co., Ltd. is a holding company which engages in the manufacture and sale of medical and pharmaceutical products.It operates through the Pharmaceuticals and Bio-Chemicals segments.The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro... 
Sector
Pharmaceuticals
Calendar
10/27Earnings Release
More about the company
Surperformance© ratings of Kyowa Hakko Kirin Co Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on KYOWA HAKKO KIRIN CO LTD
08/11 KYOWA HAKKO KIRIN : Kirin Chooses Verify Brand to Meet Compliance Mandates and G..
07/27 KYOWA HAKKO KIRIN : and Kyowa Kirin International Announce Regulatory Updates fo..
06/28 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for interim dividend
06/23 PARTNERSHIP AGREEMENT FOR A GEL FORM : Treatment for Psoriasis Vulgaris
06/22 PARTNERSHIP AGREEMENT FOR A GEL FORM : Treatment for Psoriasis Vulgaris(130KB)
06/09 KYOWA HAKKO KIRIN : Pharmaceutical firm boss applauds expansion work
05/25 KYOWA HAKKO KIRIN : Patent Issued for Method of Purifying Protein (USPTO 9650411..
05/22 KYOWA HAKKO KIRIN : FUJIFILM KYOWA KIRIN BIOLOGICS Announces Marketing Authorisa..
05/05 KYOWA HAKKO KIRIN : Kirin, Inc. and Dream Foundation Partner to Serve Adults at ..
04/28 KYOWA HAKKO KIRIN : Submits Application for Approval of Evocalcet (KHK7580) for ..
More news
Sector news : Specialty & Advanced Pharmaceuticals
02:15pDJBayer Joins Fight Against Citrus Greening Disease
08/15DJWal-Mart CEO Criticizes Trump's Virginia Response
08/15DJTwo More Corporate Executives Quit Trump Advisory Council
08/15DJCSL : Says Net Profit Rises On Immunoglobulin, Specialty-Product Sales
08/15DJWHEN 'NEW AND IMPROVED' FAILS : Insulin Maker -2-
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
04/19Ultragenyx, Kyowa Hakko Kirin And Announce Positive 24-Week Data From Adult P.. 
04/07BRIEF-Kyowa Hakko Kirin Co Ltd's phase 3 study of mogamulizumab a met its pr.. 
01/31Kyowa Hakko Kirin : Notice of Recording of Extraordinary Losses in Non-consol.. 
2016Kyowa Hakko Kirin hit with a new PhIII setback on an old Parkinson’s drug  
2016Kyowa Hakko Kirin : Application seeking Approval for Additional formulation o.. 
More tweets
Qtime:13
News from SeekingAlpha
04/10 3 THINGS IN BIOTECH YOU SHOULD LEARN : Volume 4
01/05 Ultragenyx and Kyowa Kirin announce MAA for KRN23 filed and accepted for revi..
2016 ArQule Is Undervalued Going Into Catalyst Events
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 2 267  JPY
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Nobuo Hanai President & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Koichiro Nishikawa Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD19.34%10 055
ABBVIE12.33%112 129
MERCK KGAA-6.70%14 036
JAZZ PHARMACEUTICALS PLC34.49%8 807
CONVATEC GROUP23.98%7 336
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO24.39%5 126